Try our Advanced Search for more refined results
Life Sciences - April, 2014
354 articles
- Endo To Pay $830M To Settle Most Vaginal Mesh Cases
- Pfizer unit, Mutual To Pay $73M To Settle Pay-For-Delay Claims
- US Spurns Eli Lilly's Bid To Prod Canada On Drug Patents
- House Dem To Target DOJ Nonprosecution Deals In New Bill
- Despite Dip In Pharma M&A, Oncology Remains Hot
- Democrats Seek GAO Inquiry On Women In Clinical Trials
- Ivera IV Disinfectant Cap Patents Invalid, Judge Finds
- 3rd Circ. Shuts Down Generic Fosamax Appeal
- Deals Rumor Mill: Etihad, Oprah, Pfizer
- GMO-Labeling War Wages On, Now With Congress Weighing In
- China Puts Conditions On $2.6B Merck-AZ Deal
- FDA Rips Glucose Strip Maker, Issues Safety Alert
- 3rd Circ. Won't Nix Pa. Doctor's Fen-Phen Fraud Convictions
- FDA Must Change Labeling On Heartburn Meds: Watchdog
- Female Powerbrokers Q&A: Gunster's Lila Jaber
- Female Powerbrokers Q&A: Hausfeld's Megan Jones
- Endo Birth Control Suits Belong In Georgia, Plaintiffs Say
- India Court Puts $3.2B Sun Pharma, Ranbaxy Merger On Hold
- Debate Over Categorizing Qualified Health Plans Continues
- Preemption Redemption
- Produce Documents 'Subject To' Objections At Your Own Risk
- Medtronic Is Owed $33M In Spine Device Deal, Jury Told
- Celgene Attacks Whistleblower's FCA Off-Label Suit
- SAC Fights Elan, Wyeth Investor Suit Over Insider Trading
- High Court Nailed It With Actavis, FTC's Ohlhausen Says
- $100B Pfizer Tie-Up Plan Puts Focus On US Corporate Exodus
- Appeals Court Affirms RSUI Win In Forest Lab Coverage Spat
- Deals Rumor Mill: Alstom, Allergan, Bayer
- Akin Gump Snags Former FDA Lawyer For Health Practice
- Warner Chilcott's Chewable Birth Control Patent Is Obvious
- The Golden State Warrior: Judge S. James Otero
- Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.
- Female Powerbrokers Q&A: Kirkland's Anne McClain Sidrys
- Female Powerbrokers Q&A: Porter Hedges' Joyce Soliman
- FDA Moves To Require Premarket Approval For Vaginal Mesh
- Kirkland & Ellis Reps Bristol Myers In $175M IPierian Buy
- Fla. Senate OKs Limited Legalization Of Medical Marijuana
- Justices Blast Fed. Circ. Patent Indefiniteness Test
- NJ Pharma Wholesaler Says Drugmaker Won't Share Profits
- Mintz Levin Snags Ex-Morrison & Foerster IP Expert
- Deals Rumor Mill: Alstom, Premier Oil, American Realty
- 5 Years After FERA, FCA Landscape Still Unsettled
- Pozen Says FDA Blocked Drug Products Over Quality Lapses
- Illumina Hits Ariosa With IP Suit Over Prenatal Test
- Md. High Court Says Off-Label Status Doesn't Show Drug Risks
- NJ Appeals Court Backs Arbitration In Merck Licensing Row
- AbbVie, Abbott, Others Want Testosterone Injury Cases In Ill.
- 5 Fights Over $25B Actavis-Forest Deal Merge In NY
- Watson, Mylan Slam FDA Over Generic Celebrex Decision
- New Exclusivity For Fixed-Dose Drugs Will Help Small Cos.
- FDA Bans Labels Claiming High Levels Of Omega-3
- Skadden Helps Pfizer With Potential $100B AstraZeneca Bid
- Female Powerbrokers Q&A: Patton Boggs' Laura Weidenfeld
- Female Powerbrokers Q&A: Axelrod Firm's Sheryl Axelrod
- Forest Labs Puts Up $1.5B For Furiex Pharmaceuticals
- Meda Again Shrugs Off $24B Mylan Merger Plan
- It's An Honor To Be Your Friend?: Social Media And Judges
- GCs Name Most Elite Law Firms
- 5 Pharma Ad Enforcement Trends To Watch
- Amarin Targets Apotex, Roxane Over Vascepa Generics
- AbbVie Hits Hetero USA With 2nd Suit Over Norvir Generic
- Legal And Ethical Risks Drug Companies Face In China
- Avandia User's Consumer Fraud Suit Dies In 3rd Circ.
- Deals Rumor Mill: Alstom, Dell, Allergan
- Prestige Brands To Drop $750M For Insight Pharmaceuticals
- Crowell Nabs Nixon Peabody Partner For DC Corporate Group
- FDA Won't Label Tooth Whiteners As Drugs
- Female Powerbrokers Q&A: Strasburger's Kim Moore
- Female Powerbrokers Q&A: Nicolaides' Sara Thorpe
- Takeda Won't Commit To Cover Eli Lilly For $9B Verdict
- Ark. Supreme Court Won't Rehear $1.2B Risperdal Case
- Fed. Circ. Stays Out Of USPTO Decisions To Open AIA Reviews
- Actavis Reaches Deal With Pfizer To Sell Generic Celebrex
- Life Sciences, Tech IPOs Soared In 2013
- Ex-Patent Holder Can't Appeal USPTO Ruling, Fed. Circ. Says
- Spanish Consumers Ask Watchdog To Probe Roche, Novartis
- Hyperion To Pay Up To $600M For Israeli Diabetes Drug Co.
- Female Powerbrokers Q&A: Dorsey's Liz Buckingham
- Female Powerbrokers Q&A: Williams & Connolly's Enu Mainigi
- Biomet Opts For $13.4B Sale To Zimmer, Halts IPO Plans
- USPTO Guidance Brings US In Line With Global Policy
- Legal Evolution: Back To Business
- Stryker Can't Dodge Howmedica Worker Reimbursement Suit
- Myriad Asks Fed. Circ. To Block Ambry Cancer Test In IP Row
- FDA Warns Of Fatal Risks In Widely Used Epidurals
- FDA Gets Heat On Pharma Ad Risk Disclosures
- Janssen Claims Preemption In $4M Topamax Defect Appeal
- Major Changes Come To China's Medical Device Industry
- NJ Court Skins Attys For Divulging Merck Deal Months Later
- FDA Advisory Panel Votes Down New Opioid Painkiller
- USPTO's Verdict-Nixing Power Must Be Reined In, Baxter Says
- 4 Practice Areas Generating Big Billable Hours
- Generic Cos. Seek To Appeal Androgel Dismissal Denial
- FDA Rips Providers For Shoddy Clinical Trial Oversight
- Supplement Maker Xymogen Faces Toxic Warning Label Suit
- Female Powerbrokers Q&A: Curtis' Nancy Delaney
- Female Powerbrokers Q&A: Alston Hunt's Anna Elento-Sneed
- High Health Ad Standards May Hurt Consumers: FTC Commish
- Allergan Swallows Poison Pill After $46B Valeant-Ackman Bid
- CVS Decries Novartis Kickback Suit As 'Implausible'
- Ropes & Gray SF Head Jumps To Gibson Dunn
- Hydroxycut Users Settle For Less In $14M False Ad MDL Deal
- The Accidental Advocate: Judge John E. Jones III
- Ex-Celgene Exec Gets 16 Months For Insider Trading Plot
- Mandatory Pro Bono Is Not The Answer For Practitioners
- Fed. Circ. Revives Tamiflu Case, Expands Double-Patenting
- GSK Slams Mylan's Bid For $3.1M Interest In Paxil Row
- Fed. Circ. Flips Braintree Win In Generic Suprep Suit
- Proskauer Lures Bingham Life Sciences Patent Litigator
- Low-THC Marijuana Legalization Moves Ahead In Fla. Senate
- Perrigo Wants Hurry-Up On Delayed FDA Drug Rating
- Pharma M&A Boom Means Big Payday For Wide Swath Of Firms
- Bayer Says IRS Has Burden Of Proof In $175M R&D Tax Row
- Rising Star: Kirkland & Ellis' Mike Shumsky
- Daiichi Blasts Conditional Cert. Bid In $100M Sex Bias Case
- Female Powerbrokers Q&A: BakerHostetler's Lauren Resnick
- Female Powerbrokers Q&A: Priest Johnson's Priest Johnson
- IMS Health Launches New Coverage Suit Over Antitrust Claims
- FDA Details Fast-Track Approach For Medical Devices
- Mallinckrodt, Nuvo Sue Metrics Over Generic Pennsaid
- Courts Split On Applying Therasense To Summary Judgment
- Novartis Unveils $30B In Deals To Drive Strategic Overhaul
- Generic Cos. Again Lose Bid To Shake AndroGel Suit
- Endo Hit With TCPA Junk Fax Suit Over Unsolicited Drug Ads
- Ex-Genta Exec Settles SEC Insider Suit Over Melanoma Drug
- Valeant, Ackman Put $42B Botox Maker On Takeover Hit List
- No Sanctions For Takeda Doc Destruction In Ill. Cancer Trial
- Fla. Medical Marijuana Bill Clears House Committee
- Pharma Cos. Press FDA For Track-And-Trace Flexibility
- Deals Rumor Mill: AstraZeneca, Barrick Gold, Charter
- Fed. Circ. Upholds Abbott's $16M Win Over Tarka Patent
- Rising Star: Jones Day's Colleen Heisey
- Fed. Circ. Stays Medtronic Valve Injunction In Patent Row
- Only 7 BigLaw Firms Have Women Running The Show
- Merck Delays $2.6B Buy To Win Over Chinese Antitrust Agency
- J&J, Ethicon Fight Against Pa. Pelvic Mesh Remand
- Pfizer Strikes $190M Deal To Settle Neurontin Antitrust MDL
- J&J Can't Shake Former Worker's Severance Pay Suit
- Judge OKs $64M Baxter Plasma Products Antitrust Deal
- Pronova Wants High Court's Slant On 'Public Use' Patent Bar
- Philly Mass Tort Filings Saw Steep Dip In 2013, Report Finds
- Female Powerbrokers Q&A: Allen Matkins' Amy Wintersheimer
- Female Powerbrokers Q&A: Horvitz & Levy's Lisa Perrochet
- Bayer Kills 'Misrepresentative' Mark For 'Flanax' At TTAB
- An Accused Infringer's Guide To Parallel Proceedings
- Skadden, Cleary Help Seal Sweetened $461M Chindex MBO
- Cross-Border Complexities: Keep The C-Suite Out Of Prison
- The 25 Best Law Firms For Female Partners
- Impax Can't Shake Drug Quality-Control Securities Action
- Whistleblower Wants High Court's Stance On Leave To Amend
- Nordic Naturals Defeats Stink Over Fish Oil Fraud
- Weight Loss Supplement Co. Sued Over Missing Cactus
- McKenna Long Tried To 'Destroy' Heart Tronics, Suit Says
- USC Urges Judge To Toss Ex-Football Player's Pain Med Suit
- Edwards Says Valve Ban Should Stand, Citing Scare Tactics
- $9.5B Of Venture Capital Injected In Q1, PwC Says
- Chief Justice Denies Teva's Bid To Block Generic MS Drugs
- Mylan Hit With IP Suit Over Generic Cholesterol Drug
- FDA Expands Review Of Pharma Promo Risk Perception
- Rising Star: Alston & Bird's Sarah Ernst
- 3rd Circ. Urged To Move GSK Paxil Suit Back To State Court
- FTC Wants Closer Look At $25B Actavis-Forest Labs Deal
- Female Powerbrokers Q&A: Nicolaides' Monica Sullivan
- Female Powerbrokers Q&A: Sutherland's Cynthia Shoss
- The Future Of Law Firm PR: The Good, Bad And Ugly
- FDA Approves Stronger Warning Labels For Opioids
- Perkins Coie Reels In Product Liability Pro From DLA Piper
- King & Spalding Nabs Life Sciences Pro From DLA Piper
- Eli Lilly, Others Hit Apotex With IP Suit Over Heart Drug
- Teva Offers To Post $500M Bond For Stay On Copaxone Order
- ACA Sign-Ups Hit 8M In Win For Health Care Industry
- FDA Warns Of Cancer Risks With Fibroid Removal Procedure
- Pfizer, Kaiser End Neurontin Off-Label Suit With Fee Deal
- Endo, Noven Ink Settlement Over Lidoderm Patch Patent
- American Capital Inks $291M Sale Of Pharma Co. SPL
- Executors Of BMS CEO's Estate Can't Shake $6M Tax Suit
- Teva Strikes Deal With Pfizer To Sell Generic Celebrex
- Female Powerbrokers Q&A: Dorsey's Annette Jarvis
- Female Powerbrokers Q&A: Jenner's Barbara Steiner
- FTC Continues To Target Pharmaceutical Mergers
- 8th Circ. Won't Rehear Eli Lilly Failure-To-Warn Suit En Banc
- China's Challenge To Vitamin C Price-Fixing Ruling On Point
- Ex-Stryker, Sanofi Execs Sentenced For Insider Trading
- USPTO Takes Second Shot At Patent Eligibility Guidance
- A Blow To State Encroachment On Federal Turf
- Glenmark Sues Sanofi To Clear Way For Antidiuretic
- Endo Hit With FDA Warning Over Vaginal Mesh Facility
- Cygnus Shakes Attys' Fees In Endoscopy Kit Patent Suit
- Deals Rumor Mill: Ahli, Michael Foods, SodaStream
- Astellas To Pay $7M To End Mycamine FCA Suit
- J&J Unit Bombs 6 Attempts To Ditch Humira Patent Suit
- GSK Investigating Employee Bribery In Jordan, Lebanon
- Sandoz Can't Pare Claim From Generic Remodulin Suit
- Big Pharma Tears Into FDA's Social Media Guidance
- Female Powerbrokers Q&A: Williams & Connolly's Hubbard
- Female Powerbrokers Q&A: Holland & Knight's Laurie Daniel
- Stolen Roche Cancer Drug Tampered With, Reintroduced In EU
- Medtronic Judge Backs Up Ban As Case Heads To Fed. Circ.
- Daiichi Can't Delay Class Cert. Ruling In $100M Sex Bias Suit
- The Great Persuader: 7th Circ. Chief Judge Diane Wood
- Mass. Court Upends Gov.'s Zohydro Ban
- Sen. Floats Bill to Combat Antibiotic-Resistant Microbes
- Deals Rumor Mill: ConMed, GEA Group, Telefonica
- Medicines Co. Sues Aurobindo Over Angiomax Generic
- Are You Covered For Food Product Recalls?
- Actavis, Mylan Settle IP Suit Over Generic Birth Control Drug
- Fed. Circ. Boots Injunction On Boston Scientific Catheter
- EU Parliament Approves €22B Innovation Investment Package
- Great American Seeks To Limit Meningitis Outbreak Coverage
- Female Powerbrokers Q&A: BakerHostetler's Pennington
- Female Powerbrokers Q&A: Veenker Law's Vicki Veenker
- You Should Fear The Regulator, GCs Say
- Litigation Stays Steady But Firms' Costs Keep Rising
- Heartbleed Rains On The Legal Cloud Parade
- Consequential Damages Clause At Heart Of $100M Dispute
- USTR Urged To Pressure Canada On Revoked Drug Patents
- Millennium Gets Claims Cut From Ameritox False Ad Suit
- FTC Orders Akorn To Sell Drug Lines For $640M Merger
- Herbalife Investor Files Class Action After Gov't Probes
- Bayer Escapes Bulk Of Trasylol Off-Label Marketing Suit
- Mintz Levin Nabs 3 Patent Pros For Boston Office
- DOJ Intervenes In Power Wheelchair False Claims Suit
- Medtronic Asks Fed. Circ. To Lift CoreValve Sales Ban
- Depomed Settles With Incepta, Zydus Over Nerve Pain Drug
- FDA Seeks To Stay Perrigo Suit Over Delayed Rating Update
- Philips Dodges 3rd Defibrillator Patent Row
- Deals Rumor Mill: Novartis, Disney, Shell
- J&J Surgical Mesh Recipient Wins Remand Of Injury Suit
- Myriad Loses Fed. Circ. Bid For Quick Cancer Test Appeal
- Female Powerbrokers Q&A: Rimon's Robin Powers
- Female Powerbrokers Q&A: Allen Matkins' Sandi Nichols
- Roche's Boniva Patents Are Obvious, Fed. Circ. Affirms
- Varian Settles With Pitt For $35M After Fed. Circ. Ruling
- DOJ, FBI Investigating Herbalife After FTC Civil Inquiry
- Justices Asked To Leave USPTO Verdict-Nixing Power Intact
- FDA Chief Wants Global Effort To Keep Drugs, Food Safe
- NH Sen. Urges FDA To Monitor Abuse Risks Of Zohydro
- Celgene Gets Claims Trimmed From Andrulis Drug Patent Suit
- Utah US Atty To Step Down, Rejoin Sidley Austin
- EU Agency To Inspect Testosterone Drugs In Medicine Review
- Female Powerbrokers Q&A: Susman Godfrey's Brooke Taylor
- Female Powerbrokers Q&A: Jeffer's Louise Ann Fernandez
- SPCs — We Wait In Vain For Clarity From Europe
- Keep Your Audience From Checking Email: 5 Legal Talk Tips
- Rising Stars: 2014's Top Attorneys Under 40
- The 2014 Rising Stars, By Firm
- Pharma Co. Hit With Investor Suit Over Sponsored Blog Posts
- Class Cert. Granted In Cold Medicine Marketing Row
- Nev. Judge Shuns 'Outrageous' Recusal Bid In Actos Suit
- Smith & Nephew Pays $12M To Settle ArthroCare Merger Suits
- Fed. Circ. Tells Court To Rethink Pitt's $110M Patent Award
- Nicaragua Ducks $12M Pharma Sale Suit In 11th Circ.
- Pelvic Mesh Plaintiffs Want Suits Back In Pa. State Court
- Wal-Mart Escapes Suit Over Misleading Migraine Meds
- Roche, Novartis Face French Antitrust Probe Over Eye Drugs
- Female Powerbrokers Q&A: Jenner's Susan Kohlmann
- Female Powerbrokers Q&A: Strasburger's Betsy Kamin
- DaVita Ducks Manufacturing Claims Over Dialysis Products
- Warner Chilcott Sues Over Erectile Dysfunction Drug License
- Novartis Wins Jury Verdict In Jaw-Injury Suit
- AMAG Pharma Fails To Shirk Drug-Risks Investor Suit
- 2014 Signals The Return Of The Megamerger
- Banks Sue Olympus Over $1.7B Accounting Scandal
- Workers Fund Says Takeda, Generics Delayed Diabetes Drug
- New EU Tech Regulations Will Impact Life Sciences
- 2 Inside Traders Of Celgene, Stryker Stock Get Prison Time
- St. Jude Targets Amgen Over DNA, Cancer Research Patents
- Deals Rumor Mill: Seibu, Ranbaxy, Huarong
- Female Powerbrokers Q&A: O'Brien And Ryan's Hansen
- Female Powerbrokers Q&A: Paradigm's Maureen Dorney
- Doc Destruction Likely Fired Up Jury Behind $6B Actos Verdict
- Teva Changed Its Tune on OxyContin Patent, Purdue Claims
- Branch Law Firm Says Avandia Fee Claim Must Be Arbitrated
- Del. Court Issues Warrant In WL Gore Trade Secrets Case
- Fed. Circ. Asked To Uphold Boston Scientific Injunction
- Justice Of The Peace: CIT Chief Judge Donald Pogue
- High Court Prods Generics Makers On Teva's Copaxone Bid
- Drug Design Defect Claims Post-Bartlett
- Husch Blackwell Snags Ex-Thompson Coburn Health IP Pro
- Big Pharma Consolidation Underpins Deal Making In 2014
- 2nd Circ. Asked To Reverse $153M Vitamin C Antitrust Award
- OIG Report Backs CMS In Competitive Bidding Row
- FDA Ignored Device Reclassification Process, DC Circ. Told
- Zohydro Maker Sues Mass. Gov. To Stop Drug's Ban
- Female Powerbrokers Q&A: Sheppard Mullin's Whitney Roy
- Female Powerbrokers Q&A: Saul Ewing's Debbie Spranger
- JPML Won't Join Diet Pill Suits Against USPlabs, GNC
- $9B Verdict Hammers Takeda, Eli Lilly In Actos Bellwether
- Teva Asks Supreme Court To Block Generic MS Drugs
- FTC Looks To Ax Cephalon Patent Experts In Antitrust Case
- High Court Poised To Set New Bar For Class Action Removal
- O'Melveny Nabs Patent Atty Trio For NY Office
- Eli Lilly Urges High Court To Affirm Inducement Rule
- 3rd Circ. Told GSK Violated Avandia Warranty
- Medtronic Escapes 1st Bone-Graft Device Injury Trial
- Roche Inks Potentially $450M Deal For Diagnostic Device Co.
- Sanofi Escapes Antitrust Suit Over Lovenox Contracts
- BioMed Realty Enters New Haven With $308M Office Investment
- Merck Accuses Expert Of Leaking Confidential Vioxx Docs
- Celesio Investors Hold Back Support For $5.5B McKesson Bid
- High Court Mulls Class Action Removal In Oil Royalty Row
- Female Powerbrokers Q&A: Bilzin Sumberg's Amaducci
- Female Powerbrokers Q&A: Steinman & Rodgers' Rodgers
- Latham, Wachtell Steer $5.6B Mallinckrodt-Questcor Merger
- Pros And Cons Of Trial Presentation Software Programs
- Shearman Guides Sun Pharma To $3.2B Ranbaxy Merger
- Sanofi Hid MS Drug's Checkered History, Investors Say
- Jury Says NuVasive Owes $30M In Neurovision Trademark Row
- SEC Threats Don't Help In-House Bar Prevent Retaliation
- 9th Circ. Allows Expert Testimony In Novartis Jaw Injury Row
- Mylan Claims Celgene Is Blocking Cancer Drug Generics
- J&J Inks Settlements In 76 Topamax Birth Defect Suits
- J&J Hit With $1.2M Verdict In Texas Pelvic Mesh Trial
- Direct Purchasers Denied Cert. In Transitions Antitrust Row
- Female Powerbrokers Q&A: Feinberg Day's Elizabeth Day
- Female Powerbrokers Q&A: Pillsbury's Elizabeth Moeller
- Swedish Drugmaker Meda Spurns $24B Mylan Merger Pitch
- How Omnicare Vs. Laborers Reached The High Court
- JPML Combines Boehringer Pay-For-Delay Suits In Conn.
- FDA Stays Hands-Off In Long-Awaited Health IT Report
- ITC Says Digital File Transfers Are Imports Under Tariff Act
- Apple, Ford, Pfizer, Others Team Up To Protect US Patents
- FDA Clears Overdose Antidote Amid Zohydro Uproar
- Cardinal Health Drops $320M On Medical Device Co.
- Int'l Approach Floated For Medical App Regulation
- Jenner & Block Buoys Pharm Practice With Ropes Patent Ace
- Female Powerbrokers Q&A: Wendel Rosen's Patricia Curtin
- Female Powerbrokers Q&A: Caldwell's Robyn Crowther
- FDA Bans Imports From Apotex's India Drug Plant
- 'Doc Fix' Shakes Up Wide Range Of Health Policies
- FDA To Recognize Same-Sex Couples In Regulations
- McDermott Will & Emery Launches Health Care Lobbying Arm
- IMS Health Sees Insurers Try To Jump Antitrust Coverage
- AstraZeneca Can't Shake Palmetto's Crestor Patent Fight
- J&J Unit Can't Escape TCPA Junk Fax Suit
- CORRECTED: 6 Ex-Mintz Levin Attys To Expand Cooley Life Sciences IP Team
- Female Powerbrokers Q&A: Farella Braun's Stephanie Skaff
- Female Powerbrokers Q&A: Haynes And Boone's Jan Sharry
- Pamplona Capital Buys Majority Stake In Generic-Drug Maker
- Similarities In Ark. And La. Medicaid False Claims Cases
- Burns & Levinson Snaps Up 5 Attys For Expanding IP Practice
- Weakened Patent Rights Make Trade Secrets More Attractive
- The Lion In Winter: Judge Stephen Reinhardt
- FDA Finalizes Board Member Conflict Of Interest Policies
- NuVasive Exec Defends 'Neurovision' Trademark
- GOP Reps. Want Minutes Of FDA Meeting With Trial Lawyers
- FDA Pushes For Greater Clinical Trial Patient Diversity
- Schiff Hardin Nabs Ex-Winston & Strawn IP Expert
- I-Flow Reaches Infusion Pump Patent Settlement With Rival
- Commercial Speech Issues Remain After FDA Guidance
- Steris Puts Up $175M For Medical Instrument Co.
- Female Powerbrokers Q&A: Saul Ewing's Jennifer Peterson
- Female Powerbrokers Q&A: Sheppard Mullin's Betsy McDaniel
- GSK Plans Recall After FDA Warning Over Tainted Batches